Close menu




BIONTECH SE SPON. ADRS 1

Photo credits: pixabay.com

Commented by Stefan Feulner on June 27th, 2022 | 12:12 CEST

BrainChip and Palantir with strong rebound - How does BioNTech react?

  • chips
  • Technology
  • Biotechnology

The correction on the stock markets has been going on for months. Technology stocks, in particular, have been hit hard. Due to the end of the ultra-loose monetary policy and possible larger interest rate steps, even market leaders lost more than 80% of their ground in some cases. Whether interest rate hikes can be implemented as planned in the coming months, on the other hand, appears more than questionable. After all, the spectre of recession is already hovering over the capital markets. Moreover, the historical debt levels of several countries are likely to rule out further interest rate hikes.

Read

Commented by Fabian Lorenz on June 23rd, 2022 | 11:35 CEST

Takeover fantasy: +50% in Valneva shares, and what are BioNTech and Defence Therapeutics doing?

  • Biotechnology
  • Pharma

Tension is rising in the biotech sector as the takeover merry-go-round spins faster and has now hit Valneva. Pfizer's entry caused the stock to explode 50% in three trading days. Earlier, Pfizer had announced it would acquire migraine specialist Biohaven for USD 11.6 billion. Other pharmaceutical giants are also active: Halozyme wants to swallow Antares Pharma, a specialist in urology and endocrinology, for USD 960 million. The acquisition of Sierra Oncology is costing GlaxoSmithKline around USD 1.9 billion. Like Valneva, Defence Therapeutics is about to start important trials and could attract a major partner. A takeover of BioNTech is unlikely, but the flagship German biotech should also benefit from improved sentiment in the industry. The coming week should be operationally exciting for shareholders.

Read

Commented by Nico Popp on June 22nd, 2022 | 12:32 CEST

Market-independent returns? This is how it's done! Valneva, NervGen, BioNTech

  • Biotechnology

When the stock market is in high gear, it is time for cool heads. Even if many managers are suspected of only having an eye on the next few quarters, there are still some decisions with far-reaching consequences, especially in the case of takeovers and mergers. Most recently, Pfizer acquired a stake in the vaccine manufacturer Valneva. The share price performance to date did not suggest such a step. Here is why the decision could still pay off for shareholders and what signal effect the deal will have.

Read

Commented by Armin Schulz on June 17th, 2022 | 10:45 CEST

BioNTech, Defence Therapeutics, Formycon - Biotech stocks with a lot of future potential

  • Biotechnology

A look at the NASDAQ Biotechnology Index shows that the big hype on biotech companies seems to be over for now. Since September 2021, the index has been falling, repeatedly marking new lows. However, this decline can also be seen as an opportunity because the long-term prospects for the industry are good. People are getting older, and with age comes the diseases that want to be fought. Today we look at three companies with a lot of potential for the future.

Read

Commented by Nico Popp on June 14th, 2022 | 12:26 CEST

Unheeded crisis signals! What is next: BioNTech, Lufthansa, Triumph Gold

  • Biotechnology
  • travel
  • Gold
  • Mining

There are always comeback stocks on the stock market. The airports are full of travellers who are being drawn to distant countries. So the tourism industry, and airlines too, could almost strap themselves in for a comeback. If only it weren't for the new BA.5 virus variant, which has infected large parts of the population in Portugal within a very short time. It seems investors have to choose between travel stocks and pandemic stocks when looking for comeback stocks - or is there a laughing third party?

Read

Commented by Armin Schulz on June 10th, 2022 | 11:48 CEST

BioNTech, NervGen Pharma, Valneva - Which stock will make the breakthrough in incurable diseases?

  • Biotechnology

The number of cancer patients increases every year, and only if the disease is detected at an early stage might a cure still be possible. With other diseases such as multiple sclerosis or Alzheimer's, there is no chance of a cure at all. The deterioration progresses slowly and unstoppably. COVID-19 has also shown us how vulnerable humanity is to a virus. But many biotech companies have taken up the fight against these diseases. Any drug that can stop the progression of these diseases would help those affected. Many biotech stocks have corrected significantly recently. Today we take a look at three companies and their existing potential against incurable diseases.

Read

Commented by Carsten Mainitz on June 7th, 2022 | 11:32 CEST

XPhyto, BioNTech, MorphoSys - The next price wave is coming!

  • Biotechnology

In recent years, Corona has been the most urgent topic that has moved the world and the stock markets. Health care is and remains a megatrend. It is in the nature of things that the focus changes over time. Innovative approaches or forms of drug delivery, on the other hand, remain perennial favorites. There is also a lot of progress in research against cancer. These companies will play a major role in the future.

Read

Commented by Fabian Lorenz on June 1st, 2022 | 13:44 CEST

Rain of money for BioNTech shareholders: What are Nordex and Meta Materials doing?

  • metamaterials
  • Biotechnology

BioNTech shareholders are in for a windfall. A dividend of EUR 2 per share is to be approved at today's Annual General Meeting. Also on the agenda is a share buyback program with a volume of up to USD 1.5 billion. In addition, analysts at Goldman Sachs have commented positively on the German biotech champion. Meta Materials shareholders are still a long way from a dividend. But the hot stock has announced exciting details about its fight against stroke. At Nordex, by contrast, supply chain problems, plant closures and cyberattacks dominate the headlines. But analysts see the light at the end of the tunnel - and rightly so?

Read

Commented by André Will-Laudien on May 31st, 2022 | 12:03 CEST

Watch out: BioNTech, NervGen, MorphoSys, Valneva: Biotech shares in check!

  • Biotechnology
  • biopharma

The initial sell-off in biotech stocks seems to have been digested. With last week's NASDAQ turn, spring air is now moving through the stock markets again. That is because many investors realize that, in the face of a multitude of new diseases, a major research effort is needed to protect humanity from the burgeoning dangers. Financing via the stock market was correspondingly easy for the biotech giants during the last pandemic because investors sensed big profits in the event of success. This picture is likely to repeat itself in the next movement. Where are the current opportunities in the biopharma sector?

Read

Commented by Juliane Zielonka on May 27th, 2022 | 12:39 CEST

BioNTech, XPhyto Therapeutics, Snap Inc. - Tech falls, biotech gains

  • Biotechnology
  • Technology
  • biosensor

The bearish market continues to slide. Tech companies like Snap Inc. saw share price declines of 31%. An alternative to high growth stocks are life science accelerators like XPhyto Therapeutics Corp. They are betting on the right partners and funds to bring biotech products to market faster than usual. While still with emergency approval, BioNTech is at the starting line for a Corona vaccine. Both German STIKO and partner Pfizer in the US are now targeting children for a COVID-19 vaccine.

Read